Introduction
Kaiser Permanente (KP) has a robust process for evaluating, deploying, and monitoring new types of medical technology, including devices, equipment, diagnostics, and procedures. This process provides guidance and management of new and existing medical technology to ensure that physicians of the Southern California Permanente Medical Group (SCPMG) can provide state-of-the art care. The success of the process depends on participation of a variety of internal professional and physician experts as well as other internal groups, such as the Interregional New Technologies Committee, Laboratory Committees, and Pharmacy Committees.
The process of managing medical technology uses three teams of physicians and support staff: the Medical Technology Assessment Team (MTAT), the Medical Technology Deployment Strategy Team (MTDST), and the Regional Product Council (RPC). The medical technology management process seeks to evaluate medical technology in a timely manner, using principles of evidence-based medicine and focusing on efficacy, safety, and expected improvement in health outcomes. The evaluation process also provides analytical and tactical support to SCPMG physicians by assisting them with systematic, well-thought-out deployment of medical technology. The final component of the process considers benchmark standards to coordinate purchase of the technology while ensuring that KP leverages its collective purchasing power, and provides appropriate vendor support.
Over the past two decades, the process of managing new technology in the KP Southern California Region has evolved continuously. Initially, in 1983, a Medical Technology Committee was formed to evaluate requests of local medical centers for regional approval to purchase capital medical equipment. At that time, much focus was directed on new types of imaging technology, such as computed tomography (CT) or magnetic resonance imaging (MRI).
In 1995, the Technology Assessment and Guidelines (TAG) Unit was developed to support the committee by providing evidence-based evaluation of new technology. In 1998, the California legislature enacted the Friedman-Knowles Act, which set the stage for independent medical review of coverage decisions for individual health plan enrollees. The Medical Technology Inquiry Line was created in the KP Southern California Region as a one-stop location for giving clinicians prompt access to objective, evidence-based medical information on new technology. With the support of the Permanente Federation, this service was expanded to include support for KP regions outside California.
In 2000, a process called the Medical Technology Management Process was implemented to connect the discipline of evidence-based evaluation of medical technology with a strategy for planned equipment purchase and deployment. Figure 1 shows the groups currently participating in this process, the components of which include assessing and deploying medical technology as well as responding to inquiries about it.
Technology Assessment
The health systems nology includes describing the specific health problem, the population of concern, the new technology, any alternative interventions, and the desired health outcomes. The medical problem of interest is described precisely and systematically with input from clinicians practicing in specialties relevant to the specified condition.
One of the analytical staff uses PubMed (an online bibliographic resource) to search the medical literature. The published medical literature is searched also to identify any previous assessments that may have been conducted by other organizations that use evidence-based methodology (for example, the Emergency Care Research Institute, Blue Cross/Blue Shield, or Hayes, Inc, an independent assessor of health technology). Information is sought also from government agencies, such as the US Food and Drug Administration (FDA), National Institutes of Health (NIH), National Cancer Institute (NCI), Centers for Disease Control and Prevention (CDC), and from medical specialty societies.
The MTAT carefully evaluates the quality of available evidence by thoughtfully considering such factors as number of studies and subjects, quality of investigation ( Figure 2 ), 1 consistency of study results, certainty and magnitude of possible benefits and harms, and number of potential candidates for a specified intervention.
Stating the rationale for its conclusion, the MTAT develops and forwards to interested specialty groups a recommendation based on the sufficiency of the evidence.
Technology Deployment
Technology whose use is supported by available evidence is also recommended by MTAT to the Medical Technology Deployment Strategy Team (MTDST), which considers the logistics of deployment, including forecasting the need and uses for the technology, developing a business case for its use, determining requirements for training and credentialing staff who will use the technology, and defining processes for monitoring the quality of the technology's outcomes. 
Responding to Inquiries about Technology
Physicians or Member Services Representatives with a specific patient case question or leaders with questions about new technologies can easily access informational resources on new technology by contacting the KP Southern California Region Technology Inquiry Line at 626-405-5138 or by sending an electronic inquiry to Med-Technology-AGU, Scal (KP e-mail) or scal.med-technology-agu@kp.org (Internet access). Questions can range widely-from the newest technology for targeted cancer therapy or drugs still in clinical trials to the oldest technologies-and ask, for example, "What is the role of leeches in medical therapy?" and "How can we acquire leeches appropriate for medical use?"
In response to the inquiry, the technology assessment group sends an electronic file containing several components:
• a summary and analysis of published information 
Evaluation of New Drugs
Assisted by monographs prepared by KP National Drug Information Services, the KP Pharmacy and Therapeutic Committees use an evidence-based approach to assess the safety and efficacy of new medications. Individual clinicians can obtain literature searches and information about new medications from the Drug Info line (available by phone in the KP Southern California Region), electronically at Drug-Info-Inquiry (available through KP e-mail), or Drug-Info-Inquiry@kp.org (accessed over the Internet).
The KP Biotechnology and Emerging Pharmaceuticals Technology Advisory Committee (BEPTAC) was formed in response to the exploding growth of new types of medication, including human proteins, mono- clonal antibodies, growth factors, immunomodulatory drugs, and chemotherapeutic agents. Although expensive, these drugs often represent major advances in treating the diseases for which the new medications are approved. Monitoring these medications is challenging also because they may have more widespread potential applications that have not yet been well studied; and that neither the safety of these medications, often approved after review of very limited clinical trials, nor the adverse reactions they cause, may not yet be completely understood. This concern is illustrated by the recent withdrawal of natalizumab from the market after progressive multifocal leukoencephalopathy developed in some patients who had received the drug as treatment for multiple sclerosis or Crohn's disease.
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Challenges to Use of New Medical Technology
Tension in evidence-based technology management is presented mostly by the statement that "there is insufficient evidence showing that this intervention is medically appropriate for patients." Because the process tries to "stay ahead of the curve," many assessments of medical technology initially include this statement, often reflecting existence of lag time between data collection, its presentation at specialty society meetings, and publication of the evidence in peerreviewed medical journals. In some cases, the technology that appears in a publication is already outdated and has been replaced by newer methods. Frequently, assessments must be updated and the medical literature monitored until the technology "matures" or until high-quality investigational trials are completed.
A good current example of this sequence of events is presented by virtual colonoscopy as used for detecting polyps and colorectal cancer. The medical community eagerly awaits the results of ongoing large randomized controlled trials to determine the utility of this technology compared with standard visual colonoscopy. 5 Another reason for concluding that a recommendation is supported by insufficient evidence may be that different studies present conflicting evidence. In addition, other reasons may be found for recommending against use of medical technology: existing published studies may be methodologically weak or include too small a study cohort; the magnitude of the benefit may be small; or no comparison has been made with existing technologies and therefore no evidence has been presented showing that the newer technology improves upon the older technology. In these instances, one possible solution is to deploy the new technology at KP as part of a research protocol or as a quality pilot project designed to collect data for responding to unanswered questions about whether the technology deployed within KP has improved treatment outcomes. If the technology is thus deployed as part of a research protocol, we can contribute to the health of our communities also by contributing to the peer-reviewed medical literature or by publishing our own results. With our organization's size, the interests of our clinicians, the strength of our research departments, and especially the power of an electronic medical record, the future holds much promise for us to lead in the most effective use of new medical technology. ❖
